We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pins Blame for ANDA Backlog on Lack of Inspection Resources
FDA Pins Blame for ANDA Backlog on Lack of Inspection Resources
March 2, 2011
The FDA is telling generic-drug makers that a lack of resources to conduct inspections outside of the U.S. is largely to blame for the agency’s backlog in ANDAs and is urging the industry to accept user fees as a solution the problem.